Physician profile
Stanley C Gallagher
NPI 1831125657
$1,436.41
in general payments reported to CMS, 2019-2025
28 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $70.35 · 2021: $336 · 2022: $386 · 2023: $177 · 2024: $89.74 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $276.25 | 2021-2022 | |
| Pfizer INC. | $120.79 | 2019-2025 | |
| Lilly USA, LLC | $117.61 | 2021-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $109.91 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.21 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $72.32 | 2021-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $69.59 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $67.31 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $47.19 | 2021-2022 | |
| Exact Sciences Corporation | $46.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $41.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $39.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.29 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $31.11 | 2025 | Opsumit, Uptravi |
| Biohaven Pharmaceutical Holding Company LTD. | $28.95 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.58 | 2019-2023 | Eliquis |
| Biogen, INC. | $26.19 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.46 | 2025 | Rexulti |
| Electromed, INC. | $20.46 | 2025 | Smartvest |
| Pharmacosmos Therapeutics INC. | $20.12 | 2025 | Monoferric |
| Pelvital USA, INC. | $18.74 | 2025 | |
| Ethicon US, LLC | $18.30 | 2021 | |
| Eisai INC. | $17.23 | 2021 | |
| Organon LLC | $15.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.71 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2022 | |
| Sanofi Pasteur INC. | $13.27 | 2023 | |
| Alexion Pharmaceuticals, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.